Whistleblower News: Kaiser Permanente False Claims Act Lawsuit, What The U.S. Securities Regulator Wants Chinese Issuers To Disclose, U.S. Authorities Probing Emergent Biosolutions, SPACs On Trial

Government Intervenes in False Claims Act Lawsuits Against Kaiser Permanente Affiliates for Submitting Inaccurate Diagnosis Codes to the Medicare Advantage Program

DOJ

The United States has intervened in six complaints alleging that members of the Kaiser Permanente consortium violated the False Claims Act by submitting inaccurate diagnosis codes for its Medicare Advantage Plan enrollees in order to receive higher reimbursements. read more »

Factbox: What the U.S. securities regulator wants Chinese issuers to disclose

REUTERS

The U.S. Securities and Exchange Commission will not process registrations of securities by Chinese companies unless they provide disclosures on the implications of a regulatory crackdown by Beijing and other risks, the agency said on Friday, confirming an exclusive Reuters report. read more »

U.S. authorities probing Emergent BioSolutions over COVID-19 vaccine issues - filing

REUTERS

Drug manufacturer Emergent BioSolutions Inc on Friday said it has received inquiries and subpoenas from a swathe of U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance. read more »

SPACs on Trial

NEW YORK TIMES

Trevor Milton, the founder of Nikola, is one of the most high-profile figures at the center of the boom in SPAC deals. Yesterday he was hit with criminal and civil charges by the U.S. attorney’s office in Manhattan and the S.E.C. The prosecutors accuse Milton of misleading investors about the technology for the company’s battery- and hydrogen-powered vehicles. Nikola went public in June last year by merging with a blank-check firm, VectorIQ, founded by a former G.M. executive. read more »